Resultados de Búsqueda

NICE

National Institute for Health and Clinical Excellence (NICE)

Only if: - they have not had a tyrosine kinase inhibitor before or - they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification). Lenvatinib and sorafenib are recommended only if the companies provide them according to the commercial arrangements. This recommendation is not intended to affect treatment with lenvatinib or sorafenib that was started in the NHS ...

NICE

National Institute for Health and Clinical Excellence (NICE)

Cabozantinib and vandetanib are the only systemic treatment options for unresectable, locally advanced or metastatic medullary thyroid cancer. Both drugs are currently available through the Cancer Drugs Fund for progressive and symptomatic disease. Best supportive care is the only other available option for people who cannot have cabozantinib or vandetanib. Clinical trial evidence suggests that cabozantinib is effective in delaying disease progression compared with best supportive care, but may ...

NICE

National Institute for Health and Clinical Excellence (NICE)

This recommendation is not intended to affect treatment with pembrolizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. There are currently no adjuvant immunotherapies recommended by NICE for people who have stage III melanoma with lymph node ...

NICE

National Institute for Health and Clinical Excellence (NICE)

There are currently no adjuvant treatments available for stage III BRAF V600 mutation-positive melanoma and there is a substantial risk of the cancer returning and becoming incurable. Dabrafenib with trametinib is a new adjuvant treatment aimed at curing the cancer by reducing the likelihood that it will spread. It is therefore an important development in managing stage III melanoma. Clinical trial evidence shows that dabrafenib with trametinib extends the length of time people have before ...

NICE

National Institute for Health and Clinical Excellence (NICE)

Avelumab is recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in adults, only if: - they have not had chemotherapy for metastatic disease and - the conditions in the managed access agreement for avelumab are followed. This recommendation is not intended to affect treatment with avelumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the ...